Payment overview · 2025
General Payments
$365.65
21 reported records · 9 companies
Healthcare provider profile · identity verified
Tiffany Norton, MSN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MADISONVILLE, TN · NPI 1629641139
Verified facts
What the public records show
CMS Open Payments records show Tiffany Norton, MSN received $365.65 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.39 | 20.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.08 | 19.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.02 | 15.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.52 | 14.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.33 | 8.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.21 | 8.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.23 | 5.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.46 | 4.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.41 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.65 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.39 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.08 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.08 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 101 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | 25 |
| Lisinopril | Lisinopril | 67 | 21 |
| Omeprazole | Omeprazole | 63 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 23 |
| Gabapentin | Gabapentin | 57 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 17 |
| Fluconazole | Fluconazole | 46 | 21 |
| Losartan Potassium | Losartan Potassium | 46 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 17 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Furosemide | Furosemide | 37 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 22 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 22 |
| Cephalexin | Cephalexin | 26 | 18 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Atenolol | Atenolol | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.65 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, GVOKE HYPOPEN, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error